503 related articles for article (PubMed ID: 29648516)
1. The phosphodiesterase-4 inhibitor roflumilast reverts proteolysis in skeletal muscle cells of patients with COPD cachexia.
Barreiro E; Puig-Vilanova E; Salazar-Degracia A; Pascual-Guardia S; Casadevall C; Gea J
J Appl Physiol (1985); 2018 Aug; 125(2):287-303. PubMed ID: 29648516
[TBL] [Abstract][Full Text] [Related]
2. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
3. Roflumilast N-oxide reverses corticosteroid resistance in neutrophils from patients with chronic obstructive pulmonary disease.
Milara J; Lluch J; Almudever P; Freire J; Xiaozhong Q; Cortijo J
J Allergy Clin Immunol; 2014 Aug; 134(2):314-22. PubMed ID: 24636089
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological strategies in lung cancer-induced cachexia: effects on muscle proteolysis, autophagy, structure, and weakness.
Chacon-Cabrera A; Fermoselle C; Urtreger AJ; Mateu-Jimenez M; Diament MJ; de Kier Joffé ED; Sandri M; Barreiro E
J Cell Physiol; 2014 Nov; 229(11):1660-72. PubMed ID: 24615622
[TBL] [Abstract][Full Text] [Related]
5. The discovery of roflumilast for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Calzetta L; Rogliani P; Matera MG
Expert Opin Drug Discov; 2016 Jul; 11(7):733-44. PubMed ID: 27169612
[TBL] [Abstract][Full Text] [Related]
6. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease.
Pinner NA; Hamilton LA; Hughes A
Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994
[TBL] [Abstract][Full Text] [Related]
7. Roflumilast in the management of chronic obstructive pulmonary disease.
Lipari M; Benipal H; Kale-Pradhan P
Am J Health Syst Pharm; 2013 Dec; 70(23):2087-95. PubMed ID: 24249758
[TBL] [Abstract][Full Text] [Related]
8. Roflumilast for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375
[TBL] [Abstract][Full Text] [Related]
9. Differences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexia.
Barreiro E; Sancho-Muñoz A; Puig-Vilanova E; Salazar-Degracia A; Pascual-Guardia S; Casadevall C; Gea J
J Appl Physiol (1985); 2019 Feb; 126(2):403-412. PubMed ID: 30543501
[TBL] [Abstract][Full Text] [Related]
10. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease.
Rabe KF
Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047
[TBL] [Abstract][Full Text] [Related]
11. Clinical Considerations for Roflumilast: A New Treatment for COPD.
Kelly Freeman ML
Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519
[TBL] [Abstract][Full Text] [Related]
12. Roflumilast--a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD.
Taegtmeyer AB; Leuppi JD; Kullak-Ublick GA
Swiss Med Wkly; 2012; 142():w13628. PubMed ID: 22833385
[TBL] [Abstract][Full Text] [Related]
13. Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population.
Moll K; Sun SX; Ellis JJ; Howe A; Amin A
Int J Chron Obstruct Pulmon Dis; 2015; 10():565-76. PubMed ID: 25834417
[TBL] [Abstract][Full Text] [Related]
14. A Randomized, Placebo-controlled Trial of Roflumilast. Effect on Proline-Glycine-Proline and Neutrophilic Inflammation in Chronic Obstructive Pulmonary Disease.
Wells JM; Jackson PL; Viera L; Bhatt SP; Gautney J; Handley G; King RW; Xu X; Gaggar A; Bailey WC; Dransfield MT; Blalock JE
Am J Respir Crit Care Med; 2015 Oct; 192(8):934-42. PubMed ID: 26151090
[TBL] [Abstract][Full Text] [Related]
15. Roflumilast added to triple therapy in patients with severe COPD: a real life study.
Muñoz-Esquerre M; Diez-Ferrer M; Montón C; Pomares X; López-Sánchez M; Huertas D; Manresa F; Dorca J; Santos S
Pulm Pharmacol Ther; 2015 Feb; 30():16-21. PubMed ID: 25445930
[TBL] [Abstract][Full Text] [Related]
16. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
17. Involvement of the FoxO1/MuRF1/Atrogin-1 Signaling Pathway in the Oxidative Stress-Induced Atrophy of Cultured Chronic Obstructive Pulmonary Disease Myotubes.
Pomiès P; Blaquière M; Maury J; Mercier J; Gouzi F; Hayot M
PLoS One; 2016; 11(8):e0160092. PubMed ID: 27526027
[TBL] [Abstract][Full Text] [Related]
18. Roflumilast: clinical benefit in patients suffering from COPD.
Ulrik CS; Calverley PM
Clin Respir J; 2010 Oct; 4(4):197-201. PubMed ID: 20887341
[TBL] [Abstract][Full Text] [Related]
19. Roflumilast N-oxide inhibits bronchial epithelial to mesenchymal transition induced by cigarette smoke in smokers with COPD.
Milara J; Peiró T; Serrano A; Guijarro R; Zaragozá C; Tenor H; Cortijo J
Pulm Pharmacol Ther; 2014 Aug; 28(2):138-48. PubMed ID: 24525294
[TBL] [Abstract][Full Text] [Related]
20. Roflumilast for severe COPD?
Drug Ther Bull; 2011 Apr; 49(4):45-8; quiz iii-iv. PubMed ID: 21467576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]